Fulcrum Therapeutics Strengthens Leadership Team with New Appointments
Fulcrum Therapeutics, Inc. (NASDAQ: FULC), an innovative clinical-stage biopharmaceutical company dedicated to creating groundbreaking treatments for genetically defined rare diseases, has announced the strategic appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs and Quality Assurance Officer. These key roles are crucial for advancing the lead drug candidate, losmapimod, as it moves towards its New Drug Application (NDA) submission and prepares for its upcoming commercial launch.
Introducing Isabel Kalofonos
Isabel Kalofonos joins Fulcrum Therapeutics with an impressive track record, having most recently served as Senior Vice President and Chief Commercial Officer at ImmunoGen. During her time there, she was instrumental in leading global commercial strategies for the successful launch of ELAHERE, a treatment for adults with FR?-positive, platinum-resistant epithelial ovarian cancer.
Before her tenure at ImmunoGen, Ms. Kalofonos held several senior positions at Galderma, where she played a key role in the launch preparations for NEMLUVIO, a therapy designed for atopic dermatitis. Additionally, she was a significant contributor to the global launch of TAKHZYRO while working at Takeda Pharmaceuticals. Her extensive background encompasses corporate strategy and product launches, providing her with a comprehensive perspective on the biotech landscape.
“Losmapimod is set to be a potential first-to-market oral therapy for treating FSHD, a progressive and debilitating condition for which no approved treatments currently exist,” said Ms. Kalofonos. “Joining Fulcrum at this pivotal moment as we transition to a commercial-stage organization is truly exciting.”
Heather Faulds: A Valuable Addition to Regulatory Affairs
Heather Faulds brings over 20 years of regulatory and quality assurance experience to Fulcrum. Previously serving as Senior Vice President at Alkermes, she led the regulatory team responsible for obtaining FDA approval for LYBALVI, a combination therapy for schizophrenia and bipolar disorder. Her experience also includes significant positions at Scholar Rock and Biogen, where she contributed to critical drug approvals and regulatory submissions, notably playing a role in the expedited approval of SPINRAZA for spinal muscular atrophy.
“I am excited to leverage my regulatory expertise at Fulcrum to help accelerate the delivery of therapies to patients who need them,” remarked Ms. Faulds. “With our innovative scientific foundation, I look forward to collaborating with this talented team as we prepare for our next phase of growth.”
About Fulcrum Therapeutics
Fulcrum Therapeutics is a dedicated biopharmaceutical company focused on developing small molecule therapies for patients with genetically defined rare diseases. With a strong pipeline, Fulcrum is currently advancing two lead programs: losmapimod, targeting facioscapulohumeral muscular dystrophy (FSHD), and pociredir, aimed at treating sickle cell disease (SCD). By utilizing proprietary technologies, Fulcrum aims to address the root causes of genetic disorders.
The Potential of Losmapimod
Losmapimod is a p38?/? mitogen-activated protein kinase (MAPK) inhibitor under investigation for its ability to slow the progression of FSHD. The drug has shown promising results in the Phase 2b ReDUX4 trial, indicating slower disease progression and enhanced physical function. With FDA Fast Track and Orphan Drug designations, losmapimod holds the potential to significantly change the treatment landscape for FSHD patients.
Understanding FSHD
Facioscapulohumeral muscular dystrophy (FSHD) is a rare, progressive muscle-wasting disorder that leads to the weakening and atrophy of skeletal muscles. This condition primarily affects the face, shoulders, and arms, severely impacting patients' daily activities, mobility, and independence. Approximately 30,000 individuals in the United States are affected by FSHD, highlighting a substantial unmet medical need in the field of muscular dystrophies.
Contact Information
For additional inquiries regarding Fulcrum Therapeutics, please reach out to:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
Frequently Asked Questions
1. What recent appointments has Fulcrum Therapeutics made?
Fulcrum Therapeutics has appointed Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs and Quality Assurance Officer.
2. What is the role of Isabel Kalofonos at Fulcrum?
Isabel Kalofonos will lead commercial efforts and is instrumental in preparing for the NDA submission and commercial launch of losmapimod.
3. What is losmapimod targeting?
Losmapimod is being developed as a potential first-to-market oral therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
4. What is FSHD?
FSHD is a serious, rare genetic disorder characterized by muscle weakness and atrophy, primarily affecting the face, shoulder, and upper arm muscles.
5. How can I contact Fulcrum Therapeutics for more information?
You can reach Chris Calabrese at LifeSci Advisors via email at ccalabrese@lifesciadvisors.com or by phone at 917-680-5608.
